BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 18502526)

  • 1. Acute severe hypothyroidism induced by sunitinib.
    Prat A; Serrano C; Valverde C; Calvo E
    Radiother Oncol; 2008 Oct; 89(1):124-5. PubMed ID: 18502526
    [No Abstract]   [Full Text] [Related]  

  • 2. Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.
    Ann Intern Med; 2006 Nov; 145(9):I44. PubMed ID: 17088575
    [No Abstract]   [Full Text] [Related]  

  • 3. Sunitinib-induced acute severe hypothyroidism in a case of metastatic gastrointestinal stromal tumor: A case report.
    Manir KS; Banerjee D; Bhowmick R; Roy C
    J Cancer Res Ther; 2018 Sep; 14(Supplement):S818-S819. PubMed ID: 30249914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
    Desai J; Yassa L; Marqusee E; George S; Frates MC; Chen MH; Morgan JA; Dychter SS; Larsen PR; Demetri GD; Alexander EK
    Ann Intern Med; 2006 Nov; 145(9):660-4. PubMed ID: 17088579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
    Kappers MH; van Esch JH; Smedts FM; de Krijger RR; Eechoute K; Mathijssen RH; Sleijfer S; Leijten F; Danser AH; van den Meiracker AH; Visser TJ
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3087-94. PubMed ID: 21816788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib and Thrombosis.
    Lamba G; Deol R; Shah D; Sahni R; Malhotra BK
    J Gastrointest Cancer; 2012 Sep; 43 Suppl 1():S128-30. PubMed ID: 21881834
    [No Abstract]   [Full Text] [Related]  

  • 7. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
    Wolter P; Stefan C; Decallonne B; Dumez H; Bex M; Carmeliet P; Schöffski P
    Br J Cancer; 2008 Aug; 99(3):448-54. PubMed ID: 18665181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?
    ten Freyhaus K; Homey B; Bieber T; Wilsmann-Theis D
    Br J Dermatol; 2008 Jul; 159(1):242-3. PubMed ID: 18489600
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiotoxicity associated with sunitinib.
    Hariharan S; Lowry S
    Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
    [No Abstract]   [Full Text] [Related]  

  • 10. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.
    Mannavola D; Coco P; Vannucchi G; Bertuelli R; Carletto M; Casali PG; Beck-Peccoz P; Fugazzola L
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3531-4. PubMed ID: 17595247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
    Saylor PJ; Reid TR
    J Clin Oncol; 2007 Aug; 25(23):3544-6. PubMed ID: 17687160
    [No Abstract]   [Full Text] [Related]  

  • 12. Unanswered questions regarding the management of sunitinib-induced hypothyroidism.
    Garfield D; Hercbergs A; Davis P
    Nat Clin Pract Oncol; 2007 Dec; 4(12):674. PubMed ID: 17955044
    [No Abstract]   [Full Text] [Related]  

  • 13. How does sunitinib cause hypothyroidism?
    Hershman JM; Liwanpo L
    Thyroid; 2010 Mar; 20(3):243-4. PubMed ID: 20187779
    [No Abstract]   [Full Text] [Related]  

  • 14. Sunitinib-induced pseudoporphyria.
    Sanz-Motilva V; Martorell-Calatayud A; Llombart B; Requena C; Serra-Guillén C; Nagore E; Guillén C; Traves V; Sanmartín O
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1848-50. PubMed ID: 24813651
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
    J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
    [No Abstract]   [Full Text] [Related]  

  • 16. Guillain-Barré syndrome after treatment with sunitinib malate?
    Mulherin B; Loconte NK; Holen KD
    Oncology (Williston Park); 2008 Jan; 22(1):66-7, 70-1. PubMed ID: 18251284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.
    Wong E; Rosen LS; Mulay M; Vanvugt A; Dinolfo M; Tomoda C; Sugawara M; Hershman JM
    Thyroid; 2007 Apr; 17(4):351-5. PubMed ID: 17465866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Garfield DH; Hercbergs A; Davis PJ
    J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drug Interaction between Sutent (sunitinib) and Bi-spirogyl (spiramycin-metronidazol): risk of toxicity].
    Trabelsi S; Boussen H; Gaïes E; Salouage I; El Aïdli S; Daghfous R; Loueslati MH; Lakhal M; Belkahia C
    Therapie; 2008; 63(6):475-6. PubMed ID: 19374036
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
    J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.